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Purpose: Cofﬁn–Lowry syndrome (CLS) is a rare X-linked semidominant syndromic genetic disorder that is
characterized by typical facial and radiologic ﬁndings, psychomotor and growth retardation, and various skeletal
anomalies. A distinctive paroxysmal disorder called stimulus-boundmyoclonus is clinically heterogeneous and is
generally characterized by a sudden loss of muscle tone that is regained within a few seconds and is induced by
sudden auditory or tactile stimulus. As the pathophysiology of stimulus-induced drop episodes (SIDEs) is not
well understood, there is no deﬁnite therapy for those episodes.
Methods:We report a 15-year-old female with stimulus-induced drop episodes occurringmany times a day that
resulted in failure to perform her daily activities. Because her SIDEs were misdiagnosed as atonic seizures, she
was treated with several antiepileptic drugs, including valproic acid, levetiracetam, lamotrigine, primidone, car-
bamazepine, and clobazam.
Results:We realized that her clinical and radiological ﬁndings, together with SIDEs, are compatible with Cofﬁn–
Lowry syndrome. All of her medications were discontinued following the diagnosis of SIDE, and she was started
on clonazepam. After treatment, she became more independent and was able to perform her daily activities.
Subsequently, her episodes decreased from 3 times a day to 1–2 times a month. Sodium oxybate and ﬂuoxetine
were added to the treatment protocol without remarkable improvement. Her genetic analysis revealed a
heterozygous variation of CLS.
Conclusion:We conclude that SIDE should be included in a differential diagnosis of epileptic seizures in patients
with CLS and that clonazepam is an effective choice in the treatment of SIDEs.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cofﬁn–Lowry syndrome (CLS) is an X-linked semidominant
inherited disease that was ﬁrst described independently by Cofﬁn
et al. and Lowry et al. [1,2] Temtamy et al. were the ﬁrst to recognize
that the patients reported by Cofﬁn and Lowry et al. [3] shared a similar
course. The typical clinical features of this disease are mental retarda-
tion, facial dysmorphism, puffy proximal digits, tapering digits, and
progressive skeletal changes [3]. This condition is very rare, with an
estimated incidence of 1:50,000 to 1:1,000,000; approximately 70–
80% of patients are sporadic cases [4]. Genetically, CLS is caused by
‘loss-of-function mutations’ in the Rps6ka3 gene encoding the proteine 14th Turkish Pediatric Society
logy, Giresun Prof. Dr. A. Ilhan
sun, Turkey. Tel.: +90 454 310
).
. This is an open access article underof ribosomal S6 kinase 2, a growth factor-regulated protein kinase. The
disease is characterized by sudden drop attacks induced by sound or tac-
tile stimulus without any loss of consciousness. These drop episodes last
a very short time, as little as a few seconds [5]. Typical facial features in-
clude a prominent forehead, hypertelorism, a ﬂat nasal bridge, and a
downward-sloping palpebral ﬁssure. In addition, affected individuals
have severe mental retardation, short stature, pectus excavatum or
carinatum deformity, thoracolumbar kyphosis/scoliosis, large and soft
handswith tapering of the distal short and broad ﬁngers and nails, hypo-
tonia, and facial dysmorphism characterized by a coarse facial appear-
ance [6]. ‘Stimulus-induced drop episodes’ (SIDEs) have been proposed
as a name for these nonepileptic events in patients with CLS. The patho-
physiology of SIDEs is not fully understood. Stimulus-induced drop
episodes begin at the age range of 4 to 17 years, with a mean age at
onset of around 8 years [5,7].Many different agents are used in the treat-
ment of SIDEs, including antiepileptic agents (e.g., lorazepam, clobazam,
tiagabine, felbamate, valproic acid, and carbamazepine), selective seroto-
nin reuptake inhibitors (e.g., ﬂuoxetine and escitalopram), and tricyclics
(e.g., clomipramine) [5–7]. Benzodiazepines are usually the drug ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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examine here a case of genetically conﬁrmed Cofﬁn–Lowry syndrome
in a female patient with fully manifested clinical features and drop
episodes, the latter of which partially responded to treatment with
clonazepam.Fig. 2. X-ray showing a drumstick appearance.2. Case report
A 15-year-old patient was admitted with a diagnosis of drug-
resistant epilepsy. According to the history, the patient showed normal
development until 10 years of age, except for falling a little behind her
peers in school performance. At this age, she began to experience
sudden-onset drop attacks stimulated by sound. Her prenatal history
was unremarkable, and she had a healthy older sister. The other ﬁve
subsequent pregnancies of her mother resulted in spontaneous abor-
tion. Her mother and father are ﬁrst-degree cousins. Her dysmorphic
features included orbital hypertelorism, downward-slanting palpebral
features, a ﬂat nasal bridge, a prominent forehead, anteverted nares,
thickening of the ala nasi and nasal septum, and a longmouthwith little
everted lips. Her hands are broad and puffy, with broad, typically taper-
ing ﬁngers. In addition to her facial dysmorphism, the thinning of her
distal ﬁngers and a clumsy gait were remarkable ﬁndings from the
physical examination (Fig. 1). She exhibited the skeletal deformity
of kyphosis, and the X-ray ﬁndings of her hands revealed that
their drumstick appearance was compatible with the disease (Fig. 2).
She had moderate mental retardation. Because her SIDEs were
misdiagnosed as atonic seizures, she was treated with several anti-
epileptic drugs including valproic acid, levetiracetam, lamotrigine,
primidone, carbamazepine, and clobazam. Since all of her interictal
EEGs were normal despite the sudden drop attacks, the patient was
admitted to our video monitoring unit for long-term monitoring. No
pathological appearancewas observed in the simultaneous EEGs, except
for a muscular artifact during drop episodes. Her MR imaging revealed
a normal appearance of the cerebellum and brain except for a mild
dilatation of the lateral ventricles. Her genetic analysis of the RSK2
gene supported a diagnosis of Cofﬁn–Lowry syndrome.
Sequence analysis was performed on all 22 of the exons and the
exon–intron boundaries of RPS6KA3 by using the ABI 3130 capillary
electrophoresis system. Heterozygote variation c.1973_1974insA
(p.M659Dfs*55) was found on exon 21, generating a frameshift
mutation beginning in p.Met659 and stopping at the stop codon at
position 713. As this event constitutes a truncating mutation and
frameshift variant, protein units after position 659 become defective.
As seen in Fig. 3, this variation causes damage to the functional
protein kinase domain, resulting in a novel mutation. Based on our
in silico evaluation of the functional effects by using the mutationFig. 1. Photograph of the patient showing the thinning of the distal ﬁngers.taster, Polyphen2, SIFT, and Mutation Assessor, this mutation seems to
be the disease-causing entity.
All medications were discontinued following the diagnosis of SIDE.
First, clonazepam was started because it is a treatment for this disease
that is available in our country. While receiving a daily dose of clonaze-
pam 40 mg (maximum) per day, the number of drop attacks decreased
from two or three times a day to 5–6 times a week, depending on the
stimuli. Interestingly, most of the drop attacks occurred during men-
strual cycles. The reduction in the frequency of drop attacks and the co-
ordination of the patient's movements and gait balance improved with
clonazepam treatment. Although clonazepam reduced the frequency of
drop attacks, the patient did not achieve a full recovery. For this reason,
we began a secondary therapy of sodium oxybate and ﬂuoxetine; how-
ever, this treatment regimen did not affect the clinical ﬁndings of the
patient.3. Discussion
Cofﬁn–Lowry syndrome is an X-linked inherited disease that is
characterized by typical facial and radiological dysmorphism, mental
retardation, short stature, pectus deformity, sensory–neuronal hearing
loss, and mitral valve deformity. Multipoint linkage analysis of the
many X-linked RFLP markers in 4 families was performed in 1988 [8],
and the causal gene was identiﬁed in 1996. These potential causes of
CLS have been postulated as abnormalities in the MAPK/RSK signaling
pathway [9]. The effects of RSK, which comprises 22 exons and encodes
a protein spanning 740 amino acids, include proliferation, differentia-
tion, cellular stress response, and apoptosis [10].
Cofﬁn–Lowry syndrome is usually diagnosed based on clinical
presentation and radiological ﬁndings. However, as this diagnosis is
difﬁcult tomake in very young children and females, a mutational anal-
ysis of the RPS6KA3 gene is recommended [4]. Female carriers show a
variable range of involvement in this disease, and individuals who are
heterozygous are affected less [5]. Moreover, the present case exhibited
a heterozygous variant of the disease. More than 100 different muta-
tions have been identiﬁed up to 2007; still, 50% of clinically diagnosed
patients have no mutations [6]. Highly heterogeneous loss-of-function
mutations in the RPS6KA3 gene are responsible for CLS [4]. Both the
widespread distribution of mutations and the rather large number of
exons contribute to the difﬁculties in CLS. Because there is no
Fig. 3. A truncating mutation and frameshift variant are shown. All protein units after position 659 are defective. This variation causes damage to the functional protein kinase domain.
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tions, genetic counseling is difﬁcult [4].
‘Stimulus-induced drop episodes’ (SIDEs) have been proposed as the
term for nonepileptic events in patients with CLS. Stimulus-induced
drop episodes are usually characterized by a sudden loss of muscle
tone induced after an unexpected tactile or auditory stimulus, the latter
of which is more common [5]. Stimulus-induced drop episodes are
clinically similar events as cataplexy. Clonazepam was ﬁrst used by
Nakamura et al. in their successful treatment of the drop episodes of a
16-year-old female with Cofﬁn–Lowry syndrome [8–11].
In our case, the patient did not achieve a full recovery with clonaze-
pam; therefore, we started a secondary therapy of sodium oxybate and
ﬂuoxetine. Different treatment modalities have been applied in SIDEs.
Despite our 6-month trial using sodium oxybate, no improvement in
the SIDEs was noted. The effectiveness of sodium oxybate in cases
exhibiting a sudden loss of muscle tone is considered an explanation
of the mechanism seen in cataplexy rather than in hyperekplexia [7,
12,13]. Moreover, sodium oxybate is known to be effective in treating
drop attacks, even though its exact mechanism remains undetermined
[14]. Some reports have indicated that instances of cataplexy, such as
atonic falls, are observed at younger ages, whereas hyperekplexia is
increasingly observed with advancing age [7]. Several case series have
considered the use of valproic acid, ﬂuoxetine, and clomipramine for
the treatment of SIDEs. As valproic acid has previously been used with-
out beneﬁt, we added ﬂuoxetine to the present therapy. Fluoxetine did
not contribute to an improvement of our case.
4. Conclusion
Our patient performed all of her daily activities with the aid of her
family prior to the treatment. After treatment with clonazepam, the
family indicated that their child exhibited more balanced movements.
Thus, we conclude that clonazepam is the most effective drug for the
treatment of SIDEs. Moreover, published reports have shown that the
severity and frequency of SIDEs increase with age.
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